Beta Receptor Blockers

Beta receptor blockers are medicines that reduce the effects of adrenaline and related stress hormones on the heart and other tissues, making them important tools in pharmacology and cardiovascular care. By competitively binding to beta-adrenergic receptors, these drugs limit receptor activation, slowing heart rate, reducing cardiac contractility, and decreasing renin release; selective agents primarily target beta-1 receptors, whereas nonselective agents also block beta-2 receptors. Clinicians use beta receptor blockers to manage hypertension, angina, cardiac arrhythmias, heart failure, and other conditions, although receptor selectivity and patient factors influence their effects and safety. Their study illustrates how receptor pharmacology connects molecular signaling with therapeutic outcomes.

Beta Receptor Blockers - Related Videos

Research

JoVE EoE - Neurotherapeutics

Intravenous Delivery of Receptor Blockers to Reduce Brain Edema in a Mouse Model

0 Views •

2025

Source: Zeynalov, E. et. al., Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema. J. Vis. Exp. (2016)This video demonstrates the intravenous delivery of an arginine-vasopressin (AVP) receptor antagonist in a mouse model. Transient middle cerebral artery occlusion induces brain edema. An AVP receptor antagonist is administered through a catheter in the left jugular vein, alleviating edema.

Education

JoVE Core - Pharmacology

Antihypertensive Drugs: Angiotensin II Receptor Blockers

0 Views •

2024

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

0 Views •

2023

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

0 Views •

2023

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications. α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

0 Views •

2023

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

View All Results

FAQs

Related Topics